In September 2025, TG Therapeutics presented updated six-year data from the ULTIMATE I & II Phase 3 trials of BRIUMVI® (ublituximab-xiiy) for relapsing multiple sclerosis at the ECTRIMS annual meeting ...

If you want to know who really controls TG Therapeutics, Inc. (NASDAQ:TGTX), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, ...